Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424. Wiley Online Library.
Rumgay H, Arnold M, Ferlay J, Lesi O, Cabasag CJ, Vignat J, et al. Global burden of primary liver cancer in 2020 and predictions to 2040. J Hepatol Elsevier. 2022;77:1598–606.
Galle PR, Forner A, Llovet JM, Mazzaferro V, Piscaglia F, Raoul J-L, et al. EASL Clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69:182–236. https://doi.org/10.1016/j.jhep.2018.03.019. Elsevier.
Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim T-Y, et al. IMbrave150: Updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC). Am Soc Clin Oncol. J Clin Oncol. 2021;39(3_suppl):267. https://doi.org/10.1200/JCO.2021.39.3_suppl.267.
Fulgenzi CAM, Cheon J, D’Alessio A, Nishida N, Ang C, Marron TU, et al. Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study. Eur J Cancer Elsevier. 2022;175:204–13.
Foerster F, Gairing SJ, Ilyas SI, Galle PR. Emerging immunotherapy for hepatocellular carcinoma: a guide for hepatologists. Hepatology. 2022;75:1604–26 United States.
Foerster F, Galle PR. The current landscape of clinical trials for systemic treatment of hcc. Cancers (Basel). 2021;13:1962. Multidisciplinary Digital Publishing Institute.
Article CAS PubMed Google Scholar
Llovet JM, Castet F, Heikenwalder M, Maini MK, Mazzaferro V, Pinato DJ, et al. Immunotherapies for hepatocellular carcinoma. Nat Rev Clin Oncol. 2022;19(3):151–72. https://doi.org/10.1038/s41571-021-00573-2.
Article CAS PubMed Google Scholar
Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim T-Y, et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med. 2020;382:1894–905. https://doi.org/10.1056/NEJMoa1915745. Massachusetts Medical Society.
Article CAS PubMed Google Scholar
Fang P, Hu J, Cheng Z, Liu Z, Wang J, Jiao S. Efficacy and safety of bevacizumab for the treatment of advanced hepatocellular carcinoma: a systematic review of phase II trials. PLoS One. 2012;7:e49717. Public Library of Science San Francisco, USA.
Article CAS PubMed PubMed Central Google Scholar
Ollivier-Hourmand I, Allaire M, Cervoni JP, Weil D, Ozenne V, Rautou PE, et al. Management of portal hypertension in patients treated with atezolizumab and bevacizumab for hepatocellular carcinoma. J Hepatol: Elsevier; 2022.
Bosch J, Abraldes JG, Berzigotti A, García-Pagan JC. The clinical use of HVPG measurements in chronic liver disease. Nat Rev Gastroenterol Hepatol. 2009;6:573 Nature Publishing Group.
Article CAS PubMed Google Scholar
Berzigotti A, Reig M, Abraldes JG, Bosch J, Bruix J. Portal hypertension and the outcome of surgery for hepatocellular carcinoma in compensated cirrhosis: a systematic review and meta-analysis. Hepatology. 2015;61:526–36. Wiley Online Library.
Müller L, Hahn F, Mähringer-Kunz A, Stoehr F, Gairing SJ, Foerster F, et al. Prevalence and clinical significance of clinically evident portal hypertension in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. UEG J. 2022;10(1):41–53. https://doi.org/10.1002/ueg2.12188.
De Franchis R, Bosch J, Garcia-Tsao G, Reiberger T, Ripoll C, Abraldes JG, et al. Baveno VII–Renewing consensus in portal hypertension. J Hepatol Elsevier. 2022;76:959–74.
Kihira S, Kagen AC, Vasudevan P, Jajamovich GH, Schiano TD, Andrle A-F, et al. Non-invasive prediction of portal pressures using CT and MRI in chronic liver disease. Abdom Radiol Springer. 2016;41:42–9.
Müller L, Hahn F, Mähringer-Kunz A, Stoehr F, Gairing SJ, Foerster F, et al. Immunonutritive Scoring in Patients With Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization: Prognostic Nutritional Index or Controlling Nutritional Status Score? Front Oncol. Frontiers. 2021;11:2205.
Ishizawa T, Hasegawa K, Aoki T, Takahashi M, Inoue Y, Sano K, et al. Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma. Gastroenterology Elsevier. 2008;134:1908–16.
Kim NH, Lee T, Cho YK, Kim BI, Kim HJ. Impact of clinically evident portal hypertension on clinical outcome of patients with hepatocellular carcinoma treated by transarterial chemoembolization. J Gastroenterol Hepatol. 2018;33:1397–406. Wiley Online Library.
Choi JW, Chung JW, Lee DH, Kim H-C, Hur S, Lee M, et al. Portal hypertension is associated with poor outcome of transarterial chemoembolization in patients with hepatocellular carcinoma. Eur Radiol. 2018;28:2184–93. https://doi.org/10.1007/s00330-017-5145-9.
Mejias M, Garcia-Pras E, Tiani C, Miquel R, Bosch J, Fernandez M. Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats. Hepatology. 2009;49:1245–56. Wiley Online Library.
Article CAS PubMed Google Scholar
Reiberger T, Angermayr B, Schwabl P, Rohr-Udilova N, Mitterhauser M, Gangl A, et al. Sorafenib attenuates the portal hypertensive syndrome in partial portal vein ligated rats. J Hepatol Elsevier. 2009;51:865–73.
Coriat R, Gouya H, Mir O, Ropert S, Vignaux O, Chaussade S, et al. Reversible decrease of portal venous flow in cirrhotic patients: a positive side effect of sorafenib. PLoS One. 2011;6:e16978. Public Library of Science San Francisco, USA.
Article CAS PubMed PubMed Central Google Scholar
Hidaka H, Nakazawa T, Kaneko T, Minamino T, Takada J, Tanaka Y, et al. Portal hemodynamic effects of sorafenib in patients with advanced hepatocellular carcinoma: a prospective cohort study. J Gastroenterol Springer. 2012;47:1030–5.
Pinter M, Sieghart W, Reiberger T, Rohr-Udilova N, Ferlitsch A, Peck-Radosavljevic M. The effects of sorafenib on the portal hypertensive syndrome in patients with liver cirrhosis and hepatocellular carcinoma–a pilot study. Aliment Pharmacol Ther. 2012;35:83–91. Wiley Online Library.
Article CAS PubMed Google Scholar
Procopet B, Bureau C, Peron JM. sorafenib in portal hypertension. Aliment Pharmacol Ther. 2012;36:994. Wiley Online Library.
Article CAS PubMed Google Scholar
Allaire M, Rudler M, Thabut D. Portal hypertension and hepatocellular carcinoma: des liaisons dangereuses…. Liver Int. 2021;41:1734–43. Wiley Online Library.
Iranmanesh P, Vazquez O, Terraz S, Majno P, Spahr L, Poncet A, et al. Accurate computed tomography-based portal pressure assessment in patients with hepatocellular carcinoma. J Hepatol Elsevier. 2014;60:969–74.
Qi X, An W, Liu F, Qi R, Wang L, Liu Y, et al. Virtual hepatic venous pressure gradient with CT angiography (CHESS 1601): a prospective multicenter study for the noninvasive diagnosis of portal hypertension. Radiology. 2019;290:370–7. Radiological Society of North America.
Liu Y, Tang T, Huang Y, Ji J, Yu Q, Meng X, et al. Non-invasive score using non-contrast-enhanced MRI for identification of clinically significant portal hypertension (CHESS1802): a prospective, multicentre study. Lancet. 2019;394:S75. Elsevier.
Humpire-Mamani GE, Bukala J, Scholten ET, Prokop M, van Ginneken B, Jacobs C. Fully automatic volume measurement of the spleen at ct using deep learning. Radiol Artif Intell. 2020;2:e190102. Radiological Society of North America.
Article PubMed PubMed Central Google Scholar
Linguraru MG, Sandberg JK, Jones EC, Summers RM. Assessing splenomegaly: automated volumetric analysis of the spleen. Acad Radiol Elsevier. 2013;20:675–84.
Müller L, Kloeckner R, Mähringer-Kunz A, Stoehr F, Düber C, Arnhold G, et al. Fully automated AI-based splenic segmentation for predicting survival and estimating the risk of hepatic decompensation in TACE patients with HCC. Eur Radiol. 2022. https://doi.org/10.1007/s00330-022-08737-z.
Nuffer Z, Marini T, Rupasov A, Kwak S, Bhatt S. The best single measurement for assessing splenomegaly in patients with cirrhotic liver morphology. Acad Radiol Elsevier. 2017;24:1510–6.
留言 (0)